MRG003+HX008
Phase 2Small molecule
MRG003+HX008 is one of 45 small molecule programs targeting Squamous Cell Carcinoma. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
279 competitors in Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Taxol
TevaPhase 3
Tecentriq
RochePhase 3
Paraplatin
AAvyxa
Phase 3
Libtayo
RegeneronPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Vectibix
AmgenPhase 3
Beyfortus
BeiGenePhase 3
Gilotrif
Boehringer IngelheimPhase 3
Tarceva
DDutch Society of Physicians for Pulmonology and Tuberculosis
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced or Metastatic Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MRG003+HX008. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai Miracogen Inc.